

Provided by:



Rena Rowan Breast Case Conference 2023-2024

Rena Rowan Breast Case Conference 2023-2024 - 6/1/2023

June 1, 2023

8:00 AM - 9:00 AM

PCAM South, 12th Floor, Conference Room 122 or Virtual Platform Bluejeans

Target Audience

This program has been designed for Internal Medicine - Medical Oncology, Pathology - Clinical, Radiation Oncology, Radiology, Radiology - Nuclear Radiology, Surgery - Complex General Surgical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Delineate institutional and national pathways/guidelines in the management of breast malignancy.
- 1 Discuss multidisciplinary care and discussion to improve outcomes and quality of life.
- 3 Describe the critical role of radiology and pathology in the multidisciplinary management of breast cancer
- 4 Describe how to increase awareness clinical trials at the ACC and throughout the nation and to enhance enrollment in clinical trials.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 1.00 AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

For more information, please contact
Archel Collier, Julie Mcdaniel
(215) 662-70966, (267) 970-8367

Archel.Collier@penntmedicine.upenn.edu, mcdjulie@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Rachel Jankowitz, MD	Co-Director	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Biotheranostics - 07/07/2022
Hayley Knollman, MD	Co-Director, Faculty, Other Planning Committee Member	Nothing to disclose - 05/11/2023
Yvette Bell, RN	Nurse Planner	Nothing to disclose - 02/01/2023
Tammy M Turner , MSN, RN, OCN	Nurse Planner	Nothing to disclose - 03/09/2023
Saveri Bhattacharya, DO	Other Planning Committee Member	Nothing to disclose - 05/18/2023
Ira J Bleiweiss, MD	Other Planning Committee Member	Nothing to disclose - 01/31/2023
Angela Bradbury, MD	Other Planning Committee Member	Grant or research support-Astra Zeneca Pharmaceuticals Grant or research support-Merck & Co - 02/15/2023
Ari Brooks, MS Ed	Other Planning Committee Member	Nothing to disclose - 02/23/2023
Amy Clark, MD, MD, MSCE	Other Planning Committee Member	Grant or research support-Eli Lilly Grant or research support-Novartis / Amgen (Relationship has ended) Honoraria-GE Healthcare (Relationship has ended) - 12/12/2022
Emily F Conant, MD	Other Planning Committee	Grant or research support-iCAD, Inc. Grant or

	Member	research support-Hologic, Inc. Advisor-Hologic, Inc. Advisor-iCAD, Inc. - 02/06/2023
Angela DeMichele, MD, MSCE	Other Planning Committee Member	Grant or research support-Pfizer, Inc. Grant or research support-Novartis (Advanced Health Media) Grant or research support-Genentech Grant or research support-Calithera - 12/20/2022
Tracy d'Entremont, MD	Other Planning Committee Member	Nothing to disclose - 12/07/2022
Susan Domchek, MD	Other Planning Committee Member	Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) Consulting Fee-Glaxo Smith Kline (Relationship has ended) - 01/31/2023
Leisha C Elmore, MD	Other Planning Committee Member	Nothing to disclose - 01/17/2023
Oluwadamilola Fayanju, MD, Associate Professor	Other Planning Committee Member	Nothing to disclose - 07/26/2022
Rebecca Fishman, MD	Other Planning Committee Member	Nothing to disclose - 07/26/2022
Kevin Fox, MD	Other Planning Committee Member	Nothing to disclose - 02/01/2023
Gary M Freedman, MD	Other Planning Committee Member	Nothing to disclose - 02/01/2023
William R Green, MD	Other Planning Committee Member	Nothing to disclose - 08/25/2022
Igor Makhlin, MD	Other Planning Committee Member	Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) Consulting Fee-Bayer (Relationship has ended) Consulting Fee-Gilead Sciences, Inc (Relationship has ended) - 02/15/2023
Alina Mateo	Other Planning Committee Member	Nothing to disclose - 10/20/2022
Jami D Rothman, MD, FCBC	Other Planning Committee Member	Nothing to disclose - 07/13/2022
Dahlia Sataloff, MD	Other Planning Committee Member	Nothing to disclose - 08/22/2022
Payal D Shah, MD	Other Planning Committee Member	Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended) - 02/06/2023
Lawrence N Shulman, MD	Other Planning Committee Member	Nothing to disclose - 07/18/2022
Neil Taunk, MD, MS	Other Planning Committee Member	Consulting Fee-Boston Scientific Corporation Consulting Fee-Point BioPharma Grant or research support-Varian Medical Systems - 02/14/2023
Julia Tchou, MD, PhD	Other Planning Committee Member	Advisor-Sensei bio (Relationship has ended) - 08/29/2022
stephanie kochis , PA	Physician Assistant Planner	Nothing to disclose - 07/26/2022

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.